The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Expansion In Market Value Is Forecasted For The Glycopeptide Antibiotics Market Between 2026 And 2030?
The glycopeptide antibiotics market size has experienced robust growth in recent years. It is anticipated to expand from $3.78 billion in 2025 to $4.13 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.0%. The growth observed in the past can be linked to an increase in hospital-acquired infections, the widespread application of vancomycin as standard therapy, a rising prevalence of gram-positive bacterial infections, the limited availability of alternative antibiotics, and the expansion of inpatient healthcare infrastructure.
The glycopeptide antibiotics market size is projected to experience robust expansion in the coming years, with expectations to reach $5.89 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.3%. This anticipated growth during the forecast period is propelled by the increase in multidrug-resistant pathogens, greater uptake of long-acting glycopeptides, escalating demand for antibiotic therapies administered outside of hospitals and at home, ongoing research and development into next-generation glycopeptides, and rising global healthcare expenditure. Significant trends for the forecast duration include an increasing reliance on glycopeptides for managing resistant infections, an expansion in the portfolio of lipoglycopeptide antibiotics, a rise in the hospital-based use of intravenous glycopeptides, an intensified focus on precision dosing and monitoring therapeutic outcomes, and broader application in the treatment of severe gram-positive infections.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp
What Leading Drivers Are Supporting The Glycopeptide Antibiotics Market Expansion?
The glycopeptide antibiotic market is set for growth due to the escalating incidence of gram-positive infections. These infections are instigated by gram-positive bacteria like Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes. Glycopeptide antibiotics demonstrate efficacy against numerous gram-positive bacteria by targeting their cell wall formation through a distinctive mechanism of action. An example from June 2023, presented in the Group A Streptococcal Infections: Report on Seasonal Activity in England 2022–2023 by the UK Health Security Agency, revealed a sharp increase in invasive Group A Streptococcus (iGAS) activity. By week 46 of 2023, 509 laboratory-confirmed iGAS notifications were documented, including a weekly high of 73 cases. This rise highlights an increasing burden of infectious diseases, consequently boosting the demand for potent antimicrobial therapies within the healthcare sector, and thus driving the glycopeptide antibiotic market.
How Is The Glycopeptide Antibiotics Market Broken Down By Segment Categories?
The glycopeptide antibiotics market covered in this report is segmented –
1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution
2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection
3) By Oritavancin: Oritavancin IV (Intravenous) Formulation, Oritavancin Powder for Injection
4) By Other Drugs: Teicoplanin, Glycopeptide and Lipoglycopeptide Antibiotics
What Trends Are Affecting The Direction Of The Glycopeptide Antibiotics Market?
Key players in the glycopeptide antibiotics market are concentrating on creating innovative solutions, specifically novel glycopeptide scaffolds, to secure a competitive edge. These novel scaffolds are structurally unique antibiotic frameworks, obtained through sophisticated biosynthetic methods or natural-product exploration. An example of this advancement occurred in May 2025, when a Chinese-European research consortium, recognized for its cross-continental expertise based in China, unveiled Saarvienin A. This new glycopeptide is characterized by a halogenated peptide core, an uncommon ureido linkage, and five different sugar or aminosugar components. Notably, Saarvienin A deviates from other glycopeptides by not targeting the conventional cell wall, suggesting an alternative mode of action. It also demonstrates strong in vitro efficacy against drug-resistant Gram-positive bacteria, including MRSA and vancomycin-resistant Enterococcus. Although this breakthrough represents a significant stride in combating antibiotic resistance, hurdles remain, such as its progression to clinical trials, refinement for safety, and expansion of manufacturing capacity.
Which Players Are Present In The Glycopeptide Antibiotics Market Space?
Major companies operating in the glycopeptide antibiotics market are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.
Get The Full Glycopeptide Antibiotics Market Report:
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report
Which Geographic Region Dominates The Glycopeptide Antibiotics Market?
North America was the largest region in the glycopeptide antibiotics market in 2025. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Glycopeptide Antibiotics Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report
Browse Through More Reports Similar to the Global Glycopeptide Antibiotics Market 2026, By The Business Research Company
Glycopeptide Antibiotics Market Report 2026
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report
Peptide Antibiotics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report
Antibiotics Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model